Country |
Year |
Number tested |
% infected (1) |
Setting/comments (2) (3) (4) (5) |
References |
|---|---|---|---|---|---|
Belgium |
2003-04 |
354 |
(37.35-75.96) |
LTS, DTC; serum |
2a, 2b, 8, 14 |
Czech Republic |
2002-03 |
1853 |
29.7-52 |
LTS, 12 sites in 11 of the 14 regions; PRI, 35 sites, IDUnk; serum |
3, 4 |
Denmark |
2004 |
105 |
67 |
ODD; All drug related deaths who have a blood sample taken at autopsy; IDUnk |
7 |
Germany |
2004 |
1134 |
(75.0) |
Vaccination study; serum, IDUnk |
24 |
Estonia |
2002 |
63 |
(90.5) |
LTS |
3 |
Greece |
2004 |
2227 |
44.19-61.18 / (23.58-75.76) |
DTC, LTS, OHC, OTH; serum |
1, 2, 9 |
Spain |
2003 |
669 |
(59.1-73.3) |
STR, Heroin users age 30 or less recruited in community. Injectors+non injectors. Dried blood spots. |
29, 34 |
France |
|
|
n.a. |
|
|
Ireland |
2003 |
65 |
(72.3) |
DTC; serum |
14 |
Italy |
2003 |
79160 |
65.1 / (42.1-97.2) |
DTC, PRI; saliva, serum; IDUnk |
1a, 1b |
Cyprus |
2004 |
98 |
9.1 |
DTC, PRI; serum |
1 |
Latvia |
2001 |
261 |
(83.0) |
NSP |
2 |
Lithuania |
2000 |
693 |
79 |
n.a. |
n.a. |
Luxembourg |
|
|
n.a. |
|
|
Hungary |
2003-04 |
424 |
13.98 / (30.0) |
DTC, STR, PHL; serum, saliva |
1, 2 |
Malta |
2004 |
180 |
34.4 |
DTC; serum |
2 |
Netherlands |
2004 |
60 |
(76.7) |
LTS, 5 sites; serum |
22 |
Austria |
2004 |
388 |
41.0 / (23.0-56.0) |
LTS, PHL, GPS, HTC, ODD, DTC; serum |
1, 1a, 2, 3, 4, 5 |
Poland |
2004 |
419 |
(56.0-68.3) |
DTC, LTS, STR; serum |
2, 5 |
Portugal |
2004 |
8973 |
44.5-85.3 |
DTC, Detoxification units, Outpatient units, Therapeutic communities, Public detoxification units; serum, dried blood spots; IDUnk |
10a, 23, 24 |
Slovenia |
2004 |
467 |
22.5 |
DTC; serum |
1 |
Slovakia |
2004 |
72 |
(45.87) |
DTC |
4, 7 |
Finland |
2004 |
685 |
(15.3-56.6) |
NSP; serum, saliva |
6 |
Sweden |
|
|
n.a. |
|
|
United Kingdom |
2004 |
3216 |
(27.0-74.0) |
DTC, NSP, LTS, primary care and outreach; saliva |
8, 20, 21, 31, 32 |
Bulgaria |
2004 |
1257 |
(55.8) |
DTC, NSP, LTS, outreach; 4 sites. |
1a, 1b |
Romania |
2004 |
173 |
(47.6-80.4) |
DTC; serum |
2 |
Turkey |
2004 |
38 |
(47.4) |
DTC; serum |
n.a. |
Norway |
2004 |
264 |
(68.0) |
NSP, STR; serum |
2, 2a, 2b |
Notes: This summary table is meant to give a global overview of HCV prevalence in IDUs in the EU. In this table data are reported for the most recent year available. Data sources for more than one year are used if they clearly improve generalisability (e.g. national data, out-of-treatment data). Prevalence in this table should not be compared with previous versions to follow changes over time, as inclusion of sources may vary according to data availability. For time trends see Table INF-11 to Table INF-13. (1) The figures given in brackets show local estimates (or range of estimates) within the country. (2) Saliva tests for hepatitis C antibodies underestimate prevalence. If test sensitivity is known then figures can be adjusted upwards by dividing prevalence by test sensitivity. Test sensitivity is around 70–90 % in older studies and may be up to 90–95 % in some recent studies. Figures have not been adjusted. (3) Having health problems is one selection criterion for admission to drug treatment in some countries or cities (Greece, Portugal, Rome), due to long waiting lists or special programmes for infected IDUs, and this may result in upward bias of prevalence. Prevalence from treatment data should therefore be interpreted in combination with non-treatment data. On the other hand, data from Italy and Portugal include non-IDUs and may thus underestimate prevalence in IDUs. (4) IDUnk = IDU not known, prevalence may be too low. (5) ODD = Overdose Deaths; DEM = Drug Emergencies; DTC = Drug Treatment Centres; NSP = Needle Exchanges; LTS = Low-Threshold Services; PHL = Public Health Laboratories; STI = STI Clinics; ANT = Antenatal Clinics; OHC = Other Hospital or Clinics; PRI = Prisons; ARR = Arrests; GPS = General Practitioners; HTC = HIV Testing Centres; STR = Street; OTH = Other. See Table INF-11 (Excel format). See also 'General notes for interpreting data' on the Explanatory notes and help page. | |||||